Nuvation Bio Inc. Increase (Decrease) in Other Noncurrent Assets
Nuvation Bio Inc. (NUVB) reported Increase (Decrease) in Other Noncurrent Assets of -$3.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-06
- Nuvation Bio Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was $0.00.
- Nuvation Bio Inc. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was -$3.78M.
- Nuvation Bio Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was $145.00K, a 97.64% decline year-over-year.
- Nuvation Bio Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $846.00K.
- Nuvation Bio Inc. increase (decrease) in other noncurrent assets for fiscal 2025 was $846.00K, a 85.98% decline from fiscal 2024.
- Nuvation Bio Inc. increase (decrease) in other noncurrent assets for fiscal 2024 was $6.03M, a 927.77% increase from fiscal 2023.
- Nuvation Bio Inc. increase (decrease) in other noncurrent assets for fiscal 2023 was $587.00K.
- Nuvation Bio Inc. increase (decrease) in other noncurrent assets for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month | Increase (Decrease) in Other Noncurrent Assets 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.78M 10-Q · filed 2026-08-06 | -$3.64M derived: sum of 3 quarters · filed 2026-08-06 | -$2.79M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$3.78M 10-Q · filed 2026-05-04 | -$3.64M derived: sum of 2 quarters · filed 2026-05-04 | -$2.79M derived: sum of 3 quarters · filed 2026-05-04 | -$2.79M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $145.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $991.00K derived: sum of 2 quarters · filed 2026-03-02 | $991.00K derived: sum of 3 quarters · filed 2026-08-06 | $846.00K 10-K · filed 2026-03-02 | |
| 2025-09-30 | $846.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $846.00K derived: sum of 2 quarters · filed 2026-08-06 | $701.00K 10-Q · filed 2025-11-03 | $6.84M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$145.00K 10-Q · filed 2026-08-06 | $5.99M derived: sum of 3 quarters · filed 2026-08-06 | $5.40M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$145.00K 10-Q · filed 2026-05-04 | $5.99M derived: sum of 2 quarters · filed 2026-05-04 | $5.40M derived: sum of 3 quarters · filed 2026-05-04 | $5.40M derived: sum of 4 quarters · filed 2026-05-04 | |
| 2024-12-31 | $6.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $5.54M derived: sum of 2 quarters · filed 2026-03-02 | $5.54M derived: sum of 3 quarters · filed 2026-03-02 | $6.03M 10-K · filed 2026-03-02 | $6.03M 10-K · filed 2025-03-06 |
| 2024-09-30 | -$592.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$592.00K derived: sum of 2 quarters · filed 2025-11-03 | -$104.00K 10-Q · filed 2025-11-03 | -$104.00K derived: sum of 4 quarters · filed 2025-11-03 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $488.00K 10-Q · filed 2025-08-07 | $488.00K derived: sum of 3 quarters · filed 2025-08-07 | $1.07M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $488.00K 10-Q · filed 2025-05-07 | $488.00K derived: sum of 2 quarters · filed 2025-05-07 | $1.07M derived: sum of 3 quarters · filed 2025-05-07 | $1.07M derived: sum of 4 quarters · filed 2025-05-07 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $587.00K derived: sum of 2 quarters · filed 2025-03-06 | $587.00K derived: sum of 3 quarters · filed 2025-03-06 | $587.00K 10-K · filed 2025-03-06 | |
| 2023-09-30 | $587.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $587.00K derived: sum of 2 quarters · filed 2024-11-06 | $587.00K 10-Q · filed 2024-11-06 | $587.00K derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $0.00 10-Q · filed 2024-08-05 | $0.00 derived: sum of 3 quarters · filed 2024-08-05 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-14 | $0.00 derived: sum of 2 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |